Cargando…

Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report

Immune-related adverse events (irAEs) following treatment with immune checkpoint inhibitors (ICIs) can affect almost any organ systems. Multiple-organs irAEs are a rare occurrence which makes its management and treatment very challenging. This is a case report of a 71-year-old man with advanced non-...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Chao, Yang, Meng, Jiang, Hong, Wang, Renbin, Yang, Zhaojun, Sun, Hongliang, Cui, Huijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443792/
https://www.ncbi.nlm.nih.gov/pubmed/34540659
http://dx.doi.org/10.3389/fonc.2021.664809
_version_ 1784568363374084096
author Deng, Chao
Yang, Meng
Jiang, Hong
Wang, Renbin
Yang, Zhaojun
Sun, Hongliang
Cui, Huijuan
author_facet Deng, Chao
Yang, Meng
Jiang, Hong
Wang, Renbin
Yang, Zhaojun
Sun, Hongliang
Cui, Huijuan
author_sort Deng, Chao
collection PubMed
description Immune-related adverse events (irAEs) following treatment with immune checkpoint inhibitors (ICIs) can affect almost any organ systems. Multiple-organs irAEs are a rare occurrence which makes its management and treatment very challenging. This is a case report of a 71-year-old man with advanced non-small cell lung cancer (NSCLC) who developed multiple-organs irAEs (lung, muscle, myocardium, liver, and pituitary) after a single cycle (21 days) of the BGB-A317 (Tislelizumab). After more than two months of immunosuppression treatment with glucocorticoids, the tumor and inflammatory lesions in the lung were reduced. The levels of serum creatase, cardiac troponin T (TNT), and hepatic transaminase were also reduced. Four months after the termination of ICI therapy, the lung tumor reappeared in the previous site. This rare case report supplies several experiences in the management of multiple-organs irAEs, including full-scale monitoring of immunological indicators, early differential diagnosis, and prompt glucocorticoid therapy. This patient was not a candidate for the ICI re-challenge therapy due to the number and seriousness of irAEs. Multiple-organs irAEs add complexity to the management, and additional research is needed to develop optimal therapeutic guidelines.
format Online
Article
Text
id pubmed-8443792
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84437922021-09-17 Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report Deng, Chao Yang, Meng Jiang, Hong Wang, Renbin Yang, Zhaojun Sun, Hongliang Cui, Huijuan Front Oncol Oncology Immune-related adverse events (irAEs) following treatment with immune checkpoint inhibitors (ICIs) can affect almost any organ systems. Multiple-organs irAEs are a rare occurrence which makes its management and treatment very challenging. This is a case report of a 71-year-old man with advanced non-small cell lung cancer (NSCLC) who developed multiple-organs irAEs (lung, muscle, myocardium, liver, and pituitary) after a single cycle (21 days) of the BGB-A317 (Tislelizumab). After more than two months of immunosuppression treatment with glucocorticoids, the tumor and inflammatory lesions in the lung were reduced. The levels of serum creatase, cardiac troponin T (TNT), and hepatic transaminase were also reduced. Four months after the termination of ICI therapy, the lung tumor reappeared in the previous site. This rare case report supplies several experiences in the management of multiple-organs irAEs, including full-scale monitoring of immunological indicators, early differential diagnosis, and prompt glucocorticoid therapy. This patient was not a candidate for the ICI re-challenge therapy due to the number and seriousness of irAEs. Multiple-organs irAEs add complexity to the management, and additional research is needed to develop optimal therapeutic guidelines. Frontiers Media S.A. 2021-09-02 /pmc/articles/PMC8443792/ /pubmed/34540659 http://dx.doi.org/10.3389/fonc.2021.664809 Text en Copyright © 2021 Deng, Yang, Jiang, Wang, Yang, Sun and Cui https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Deng, Chao
Yang, Meng
Jiang, Hong
Wang, Renbin
Yang, Zhaojun
Sun, Hongliang
Cui, Huijuan
Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report
title Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report
title_full Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report
title_fullStr Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report
title_full_unstemmed Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report
title_short Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report
title_sort immune-related multiple-organs injuries following ici treatment with tislelizumab in an advanced non-small cell lung cancer patient: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443792/
https://www.ncbi.nlm.nih.gov/pubmed/34540659
http://dx.doi.org/10.3389/fonc.2021.664809
work_keys_str_mv AT dengchao immunerelatedmultipleorgansinjuriesfollowingicitreatmentwithtislelizumabinanadvancednonsmallcelllungcancerpatientacasereport
AT yangmeng immunerelatedmultipleorgansinjuriesfollowingicitreatmentwithtislelizumabinanadvancednonsmallcelllungcancerpatientacasereport
AT jianghong immunerelatedmultipleorgansinjuriesfollowingicitreatmentwithtislelizumabinanadvancednonsmallcelllungcancerpatientacasereport
AT wangrenbin immunerelatedmultipleorgansinjuriesfollowingicitreatmentwithtislelizumabinanadvancednonsmallcelllungcancerpatientacasereport
AT yangzhaojun immunerelatedmultipleorgansinjuriesfollowingicitreatmentwithtislelizumabinanadvancednonsmallcelllungcancerpatientacasereport
AT sunhongliang immunerelatedmultipleorgansinjuriesfollowingicitreatmentwithtislelizumabinanadvancednonsmallcelllungcancerpatientacasereport
AT cuihuijuan immunerelatedmultipleorgansinjuriesfollowingicitreatmentwithtislelizumabinanadvancednonsmallcelllungcancerpatientacasereport